Statistics

Total Visits

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials102

Select a period of time:

Number of views in the range

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials26

Views

Views
June 20251
July 202515
August 20250
September 20252
October 20251
November 20255
December 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil11
United States10
Argentina1
Ecuador1
United Kingdom1
Morocco1
Venezuela1
 

Top cities views

Views
Rio de Janeiro2
Albany1
Ashburn1
Barquisimeto1
Buffalo1
Campos dos Goytacazes1
Curitiba1
Fort Worth1
Guarapuava1
Guayaquil1